title: CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival.
authors.forename: Clemens
authors.initials: C
authors.lastname: Thoma
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives*
chemical_list: D000813:Anilides; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011725:Pyridines; D020123:Sirolimus